Jeff Williams, Chief Executive Officer
Prior to founding Clinipace Worldwide, Jeff held several executive-level positions within the life sciences and software industries. As CEO of NextAudio, an early pioneer in Internet-based services, he successfully merged the company with Koz to create Mediaspan, a company that expanded to more than 200 employees and earned more than $26 million in sales.
Additionally, Jeff was a co-founder of HealthMatics, one of the first electronic medical records (EMR) software providers, which was sold to A4 Health and later acquired by Allscripts. Prior to these technology endeavors, Jeff spent 10 years at Ciba (now Novartis) and two years at Glaxo Wellcome. During this period, he pioneered some of the earliest direct-to-consumer advertising campaigns within the industry and shared marketing-based responsibility for one of the largest Phase IV studies ever conducted at the time (more than 10,000 patients).
Jeff served on the Board of Directors for CampbellAlliance (prior to its acquisition by InVentiv) and currently serves on the board at Cathedral Corporation, a leader in print and electronic data output services.
Jeff has a Bachelor of Science degree in Chemistry with minors in Business Management and Biology from the University of Tampa.
In 2007, Jeff was named to the PharmaVoice 100, an annual listing of the 100 most influential people in the life sciences industry.
Christopher Porter, President and General Counsel
Chris co-founded Clinipace Worldwide and currently services as president and general counsel. In this role, Chris leads corporate and business development, legal affairs, medical affairs, human resources, therapeutic leadership, regulatory and strategic development, and corporate quality assurance.
Prior to Clinipace Worldwide, Chris served as vice president of corporate development and legal affairs for Drug Safety Alliance, Inc. (DSA). Additionally, Chris served as group manager of the Siebel Venture Group, Siebel Systems, Inc., where he was responsible for all of Siebel’s venture transactions and management of a $30M portfolio with a specific interest in life science technology opportunities. Chris joined Siebel through Siebel’s $542M acquisition of OpenSite Technologies where Chris was the original member of the business development group.
Chris has held various other positions in the life science industry including positions in sales and marketing for Glaxo, Inc. and Quintiles Transnational, and manager of legal and business affairs for AM Pappas & Associates, one of the largest life science venture capital firms in the Southeast.
Chris received his Juris Doctor and Master of Business Administration from the University of North Carolina at Chapel Hill in 1998. Chris also earned his Bachelor of Arts in Journalism/Advertising from UNC-CH in 1992.
In 2008 Chris was named to the PharmaVoice 100, an annual listing of the 100 most influential people in the life sciences industry.
Ron Marks, PhD, Chief Scientific Officer
Ron co-founded Clinipace Worldwide to bring to market an eClinical trial solution that he helped develop at the University of Florida. Ron and his team in the Division of Biostatistics developed a web-based electronic clinical trial system beginning in 1996 that was used to support a 22,000 patient Phase 4 cardiology clinical trial that ran at 870 primary physician sites in 10 countries for 5 years. The University received a patent on multiple aspects of the eClinical system.
Ron was trained as a Biostatistician. He received his MS and PhD in Statistics at the University of Florida and joined the Division of Biostatistics faculty at the J Hillis Miller Health Center at the University of Florida upon graduation. He served on the faculty for 30 years and as Director for 18 years.
Since joining Clinipace Worldwide, Ron serves as Chief Scientific Officer and Global Director of Biostatistics.
Daryl Porter, Chief Technology Officer
Daryl leads the service engineering, product engineering, and cloud computing infrastructure teams.
Prior to Clinipace Worldwide, Daryl spent 18 years at Oracle Corporation and held several executive level positions in both enterprise product development and enterprise support services. Daryl spent most of his career at Oracle in the Database Tools Division as a programmer, manager and vice president where he managed teams ranging from 3 to 300 with commensurate responsibilities around strategic direction, operational execution, budget, and performance.
Daryl concluded his tenure at Oracle as the Vice President of Advanced Support Services. He was responsible for streamlining software life cycle services for global teams of over 10,000 software professionals in five countries and conducting architectural assessments for Fortune 100 Customers in the healthcare, government, financial and telecomm industries to accelerate the adoption of GRID computing and LINUX. He also managed the Oracle-Red Hat relationship as the Oracle OnDemand Service Executive. Additionally, he was an integral member of the M&A technical team tasked with conducting due diligence on Oracle’s acquisitions of Siebel and PeopleSoft.
Daryl holds an Master of Science in Engineering (MSE) in Computer Science from Princeton University, a Bachelor of Science in Mathematical Sciences from the University of North Carolina at Chapel Hill, and is a member of Phi Beta Kappa.
Mark Harvill, Chief Operating Officer
Mark leads the company’s global clinical service delivery organization, including clinical operations (project management and monitoring), global central services (biostatistics, site management & data management), and pharmacovigilance and patient safety management.
Mark joined Clinipace Worldwide through its acquisition of Paragon Biomedical. Mark joined Paragon in 2006 and has 20+ years of CRO management experience.
He previously served as senior vice president of an international data services CRO, where he directed global project management, business development, and strategic customer relationships. Before entering the CRO field, Mark was with The Financial Relations Board, where he was responsible for the development and implementation of investor relations programs for companies in the biotechnology and healthcare industries.
Mark earned a master’s degree in journalism with an emphasis in investor relations from Michigan State University, and a bachelor’s degree in public relations from Oklahoma Christian University.
Mark Ubert, Chief Financial Officer
Mark leads the accounting, financial reporting, treasury, and tax team for the company. Mark has more than 25 years of experience in various finance and accounting leadership roles, including more than 15 years in CFO-level positions in the life sciences and healthcare industries.
Mark’s professional career began in the public accounting industry, where he was with KPMG and Ernst & Young. Subsequently, he has held various leadership positions with increasing responsibility serving in the capacity of senior financial executive with responsibilities including fund raising, strategic planning, operational support, and financial reporting. Some of Mark’s key success initiatives were in the areas of enhancing domestic and international financial processes and procedures, private equity investor and banker relationships, operational metric tracking and reporting, treasury/cash management functions, financial reporting, and international tax planning. He worked with industry-leading companies such as Omnicare and Quintiles as well as other mid-tier CROs.
Mark’s global experience includes divisional financial leadership with oversight of multiple operational locations as well as merger, acquisition, and expansion planning within Europe, Asia, and Latin America. Additionally, Mark lived in Tokyo for five years serving as CFO for Quintiles-Japan.
Mark received a Master of Business Administration (MBA) from the Keller Graduate Program at DeVry University and earned a Bachelor of Business Administration (BBA) from Washburn University. He is a Certified Public Accountant and a member of the American Institute of CPAs.